Your browser doesn't support javascript.
loading
A Sensitive and Cost-Effective Chemiluminescence ELISA for Measurement of Amyloid-ß 1-42 Peptide in Human Plasma.
Mehta, Pankaj D; Patrick, Bruce A; Miller, David L; Coyle, Patricia K; Wisniewski, Thomas.
Afiliación
  • Mehta PD; New York State Institute for Basic Research in Developmental Disabilities, Staten Island, NY, USA.
  • Patrick BA; New York State Institute for Basic Research in Developmental Disabilities, Staten Island, NY, USA.
  • Miller DL; New York State Institute for Basic Research in Developmental Disabilities, Staten Island, NY, USA.
  • Coyle PK; Department of Neurology, Stony Brook University, Stony Brook, NY, USA.
  • Wisniewski T; Center for Cognitive Neurology, New York University School of Medicine, New York, NY, USA.
J Alzheimers Dis ; 78(3): 1237-1244, 2020.
Article en En | MEDLINE | ID: mdl-33252086
BACKGROUND: Amyloid-ß42 (Aß42) is associated with plaque formation in the brain of patients with Alzheimer's disease (AD). Studies have suggested the potential utility of plasma Aß42 levels in the diagnosis, and in longitudinal study of AD pathology. Conventional ELISAs are used to measure Aß42 levels in plasma but are not sensitive enough to quantitate low levels. Although ultrasensitive assays like single molecule array or immunoprecipitation-mass spectrometry have been developed to quantitate plasma Aß42 levels, the high cost of instruments and reagents limit their use. OBJECTIVE: We hypothesized that a sensitive and cost-effective chemiluminescence (CL) immunoassay could be developed to detect low Aß42 levels in human plasma. METHODS: We developed a sandwich ELISA using high affinity rabbit monoclonal antibody specific to Aß42. The sensitivity of the assay was increased using CL substrate to quantitate low levels of Aß42 in plasma. We examined the levels in plasma from 13 AD, 25 Down syndrome (DS), and 50 elderly controls. RESULTS: The measurement range of the assay was 0.25 to 500 pg/ml. The limit of detection was 1 pg/ml. All AD, DS, and 45 of 50 control plasma showed measurable Aß42 levels. CONCLUSION: This assay detects low levels of Aß42 in plasma and does not need any expensive equipment or reagents. It offers a preferred alternative to ultrasensitive assays. Since the antibodies, peptide, and substrate are commercially available, the assay is well suited for academic or diagnostic laboratories, and has a potential for the diagnosis of AD or in clinical trials.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fragmentos de Péptidos / Ensayo de Inmunoadsorción Enzimática / Péptidos beta-Amiloides / Enfermedad de Alzheimer / Mediciones Luminiscentes Tipo de estudio: Diagnostic_studies / Health_economic_evaluation / Observational_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Alzheimers Dis Asunto de la revista: GERIATRIA / NEUROLOGIA Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Países Bajos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fragmentos de Péptidos / Ensayo de Inmunoadsorción Enzimática / Péptidos beta-Amiloides / Enfermedad de Alzheimer / Mediciones Luminiscentes Tipo de estudio: Diagnostic_studies / Health_economic_evaluation / Observational_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Alzheimers Dis Asunto de la revista: GERIATRIA / NEUROLOGIA Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Países Bajos